Immunohistochemical Study of Chordomas to Improve Their Diagnosis and Prognosis Care

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04486820

Acronym

CHORDOMES

Enrollment

Registered

2020-07-27

Start date

2020-04-01

Completion date

2020-07-01

Last updated

2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chordoma

Keywords

Immunohistochemical, PD-L1, CD8, CDX2, INSM1, FOXA1

Brief summary

Chordomas are very rare malignant tumors, chemo-resistant with high propensity for recurrence. The role of immunotherapy in these patients remains largely unexplored while PD-L1 and CD8 status in the micro-environment of chordomas is basically not known. Similarly, this tumor often poses diagnostic difficulties due to its resemblance with metastasis or chondrosarcoma, thus, it would be useful to know the expression status of factors used during the work-up of metastatic or mesenchymal tumors, like CDX2, INSM1 and FOXA1, which remains unknown for chordomas. Thus, the aim of the study is to explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression in a series of chordomas and compare it with clinico-pathological and prognostic features.

Detailed description

Retrospective, non-interventional study. A series of chordomas will be analyzed for detailed histologic features and for various immunohistochemical factors and results will be compared with clinical factors, like overall and disease-free survival.

Interventions

OTHERAnalysis Immunohistochemical

Analysis of histological material for immunohistochemical study. To explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients diagnosed with chordoma * Sufficient histological material available * Tumor expression of brachyury

Exclusion criteria

\- Insufficient histological material

Design outcomes

Primary

Measure	Time frame	Description
Expression of FOXA1	Baseline	measured by immunohistochemical method
Expression of CD8	Baseline	measured by immunohistochemical method
Expression of CDX2	Baseline	measured by immunohistochemical method
Expression of INSM1	Baseline	measured by immunohistochemical method
Expression of PD-L1	Baseline	measured by immunohistochemical method

Secondary

Measure	Time frame	Description
Tumor location	Baseline	data collected in personal health records.
survival of patients after diagnosis with or without progression	Baseline	data collected in personal health records.
Histological type of tumor	Baseline	data collected in personal health records.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026